AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. DTIL
  4. [Form 4] Precision BioSciences, Inc. Insider Trading Activity

[Form 4] Precision BioSciences, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Positive)
Form Type
4
Rhea-AI Filing Summary

Precision BioSciences (NASDAQ: DTIL) filed a Form 4 disclosing that director Kevin Buehler purchased 5,076 shares of common stock on 25 Jun 2025 at a weighted-average price of $4.16 per share (trade range: $4.16鈥�$4.18). After the transaction, Buehler directly owns 28,137 shares, an increase of roughly 22% in his personal stake. The transaction was coded 鈥淧鈥� for an open-market purchase, and the filing reports no sales or derivative security activity. No Rule 10b5-1 trading plan was indicated.

Precision BioSciences (NASDAQ: DTIL) ha depositato un Modulo 4 rivelando che il direttore Kevin Buehler ha acquistato 5.076 azioni ordinarie il 25 giugno 2025 a un prezzo medio ponderato di 4,16 $ per azione (intervallo di prezzo: 4,16鈥�4,18 $). Dopo la transazione, Buehler possiede direttamente 28.137 azioni, un aumento di circa il 22% della sua partecipazione personale. La transazione 猫 stata classificata come 鈥淧鈥� per un acquisto sul mercato aperto, e il deposito non riporta vendite n茅 attivit脿 su titoli derivati. Non 猫 stato indicato alcun piano di trading secondo la Regola 10b5-1.

Precision BioSciences (NASDAQ: DTIL) present贸 un Formulario 4 revelando que el director Kevin Buehler 肠辞尘辫谤贸 5,076 acciones ordinarias el 25 de junio de 2025 a un precio promedio ponderado de $4.16 por acci贸n (rango de precio: $4.16鈥�$4.18). Tras la transacci贸n, Buehler posee directamente 28,137 acciones, un aumento de aproximadamente el 22% en su participaci贸n personal. La transacci贸n fue clasificada como 鈥淧鈥� para una compra en mercado abierto, y el informe no registra ventas ni actividad con valores derivados. No se indic贸 ning煤n plan de negociaci贸n bajo la Regla 10b5-1.

Precision BioSciences (NASDAQ: DTIL)電� 鞚挫偓 Kevin Buehler臧� 2025雲� 6鞗� 25鞚检棎 氤错喌欤� 5,076欤�毳� 欤茧嫻 臧�欷戫弶攴� 臧�瓴� $4.16(瓯半灅 氩旍渼: $4.16鈥�$4.18)鞐� 毵れ垬頄堧嫟瓿� 鞁犼碃頃� Form 4毳� 鞝滌稖頄堨姷雼堧嫟. 瓯半灅 頉� Buehler電� 歆侅爲鞝侅溂搿� 28,137欤�毳� 氤挫湢頃橁矊 霅橃棃鞙茧┌, 鞚措姅 臧滌澑 歆�攵勳澊 鞎� 22% 歃濌皜頃� 靾橃箻鞛呺媹雼�. 鞚� 瓯半灅電� 瓿店皽 鞁滌灔 毵れ垬搿� 攵勲霅� 鈥淧鈥� 旖旊摐臧� 攵�鞐悩鞐堨溂氅�, 鞁犼碃靹滌棎電� 毵る弰雮� 韺岇儩靸來拡 瓯半灅 雮挫棴鞚� 鞐嗢姷雼堧嫟. 10b5-1 攴滌箼鞐� 霐半ジ 瓯半灅 瓿勴殟鞚� 氇呾嫓霅橃 鞎婌晿鞀惦媹雼�.

Precision BioSciences (NASDAQ : DTIL) a d茅pos茅 un formulaire 4 r茅v茅lant que le directeur Kevin Buehler a achet茅 5 076 actions ordinaires le 25 juin 2025 脿 un prix moyen pond茅r茅 de 4,16 $ par action (fourchette de prix : 4,16鈥�4,18 $). Apr猫s cette transaction, Buehler poss猫de directement 28 137 actions, soit une augmentation d'environ 22 % de sa participation personnelle. La transaction a 茅t茅 cod茅e 芦 P 禄 pour un achat sur le march茅 ouvert, et le d茅p么t ne mentionne aucune vente ni activit茅 sur titres d茅riv茅s. Aucun plan de n茅gociation selon la r猫gle 10b5-1 n鈥檃 茅t茅 indiqu茅.

Precision BioSciences (NASDAQ: DTIL) reichte ein Formular 4 ein, in dem offengelegt wird, dass der Direktor Kevin Buehler am 25. Juni 2025 5.076 Aktien des Stammkapitals zu einem gewichteten Durchschnittspreis von 4,16 $ pro Aktie (Handelsspanne: 4,16鈥�4,18 $) erworben hat. Nach der Transaktion besitzt Buehler direkt 28.137 Aktien, was einer Steigerung seines pers枚nlichen Anteils um etwa 22% entspricht. Die Transaktion wurde mit 鈥濸鈥� f眉r einen Kauf am offenen Markt kodiert, und die Meldung verzeichnet keine Verk盲ufe oder Derivateaktivit盲ten. Es wurde kein Handelsplan gem盲脽 Regel 10b5-1 angegeben.

Positive
  • Director Kevin Buehler increased his direct ownership by 5,076 DTIL shares (+22%) through an open-market purchase at an average $4.16 price
Negative
  • None.

Insights

TL;DR: Small insider buy shows modest confidence; impact likely neutral.

The Form 4 reveals a roughly $21 k open-market purchase by director Kevin Buehler, lifting his direct holdings by about 22% to 28,137 shares. While the percentage increase exceeds the 5% materiality threshold, the dollar value is immaterial relative to Precision BioSciences鈥� capitalization, so immediate market impact should be limited. Absence of concurrent sales or option exercises offers a marginally positive sentiment signal but not a decisive catalyst.

Precision BioSciences (NASDAQ: DTIL) ha depositato un Modulo 4 rivelando che il direttore Kevin Buehler ha acquistato 5.076 azioni ordinarie il 25 giugno 2025 a un prezzo medio ponderato di 4,16 $ per azione (intervallo di prezzo: 4,16鈥�4,18 $). Dopo la transazione, Buehler possiede direttamente 28.137 azioni, un aumento di circa il 22% della sua partecipazione personale. La transazione 猫 stata classificata come 鈥淧鈥� per un acquisto sul mercato aperto, e il deposito non riporta vendite n茅 attivit脿 su titoli derivati. Non 猫 stato indicato alcun piano di trading secondo la Regola 10b5-1.

Precision BioSciences (NASDAQ: DTIL) present贸 un Formulario 4 revelando que el director Kevin Buehler 肠辞尘辫谤贸 5,076 acciones ordinarias el 25 de junio de 2025 a un precio promedio ponderado de $4.16 por acci贸n (rango de precio: $4.16鈥�$4.18). Tras la transacci贸n, Buehler posee directamente 28,137 acciones, un aumento de aproximadamente el 22% en su participaci贸n personal. La transacci贸n fue clasificada como 鈥淧鈥� para una compra en mercado abierto, y el informe no registra ventas ni actividad con valores derivados. No se indic贸 ning煤n plan de negociaci贸n bajo la Regla 10b5-1.

Precision BioSciences (NASDAQ: DTIL)電� 鞚挫偓 Kevin Buehler臧� 2025雲� 6鞗� 25鞚检棎 氤错喌欤� 5,076欤�毳� 欤茧嫻 臧�欷戫弶攴� 臧�瓴� $4.16(瓯半灅 氩旍渼: $4.16鈥�$4.18)鞐� 毵れ垬頄堧嫟瓿� 鞁犼碃頃� Form 4毳� 鞝滌稖頄堨姷雼堧嫟. 瓯半灅 頉� Buehler電� 歆侅爲鞝侅溂搿� 28,137欤�毳� 氤挫湢頃橁矊 霅橃棃鞙茧┌, 鞚措姅 臧滌澑 歆�攵勳澊 鞎� 22% 歃濌皜頃� 靾橃箻鞛呺媹雼�. 鞚� 瓯半灅電� 瓿店皽 鞁滌灔 毵れ垬搿� 攵勲霅� 鈥淧鈥� 旖旊摐臧� 攵�鞐悩鞐堨溂氅�, 鞁犼碃靹滌棎電� 毵る弰雮� 韺岇儩靸來拡 瓯半灅 雮挫棴鞚� 鞐嗢姷雼堧嫟. 10b5-1 攴滌箼鞐� 霐半ジ 瓯半灅 瓿勴殟鞚� 氇呾嫓霅橃 鞎婌晿鞀惦媹雼�.

Precision BioSciences (NASDAQ : DTIL) a d茅pos茅 un formulaire 4 r茅v茅lant que le directeur Kevin Buehler a achet茅 5 076 actions ordinaires le 25 juin 2025 脿 un prix moyen pond茅r茅 de 4,16 $ par action (fourchette de prix : 4,16鈥�4,18 $). Apr猫s cette transaction, Buehler poss猫de directement 28 137 actions, soit une augmentation d'environ 22 % de sa participation personnelle. La transaction a 茅t茅 cod茅e 芦 P 禄 pour un achat sur le march茅 ouvert, et le d茅p么t ne mentionne aucune vente ni activit茅 sur titres d茅riv茅s. Aucun plan de n茅gociation selon la r猫gle 10b5-1 n鈥檃 茅t茅 indiqu茅.

Precision BioSciences (NASDAQ: DTIL) reichte ein Formular 4 ein, in dem offengelegt wird, dass der Direktor Kevin Buehler am 25. Juni 2025 5.076 Aktien des Stammkapitals zu einem gewichteten Durchschnittspreis von 4,16 $ pro Aktie (Handelsspanne: 4,16鈥�4,18 $) erworben hat. Nach der Transaktion besitzt Buehler direkt 28.137 Aktien, was einer Steigerung seines pers枚nlichen Anteils um etwa 22% entspricht. Die Transaktion wurde mit 鈥濸鈥� f眉r einen Kauf am offenen Markt kodiert, und die Meldung verzeichnet keine Verk盲ufe oder Derivateaktivit盲ten. Es wurde kein Handelsplan gem盲脽 Regel 10b5-1 angegeben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Buehler Kevin
(Last) (First) (Middle)
C/O PRECISION BIOSCIENCES, INC.
302 E. PETTIGREW ST, SUITE A-100
(Street)
DURHAM NC 27701
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PRECISION BIOSCIENCES INC [ DTIL ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/25/2025 P 5,076 A $4.16(1) 28,137 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.16 to $4.18. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.
Remarks:
/s/ Dario Scimeca, Attorney-in-fact for Kevin Buehler 06/27/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many DTIL shares did director Kevin Buehler buy on June 25, 2025?

He purchased 5,076 shares of Precision BioSciences common stock.

What was the average purchase price for the shares acquired by DTIL's director?

The weighted-average price was approximately $4.16 per share, with transactions between $4.16 and $4.18.

What is Kevin Buehler's total direct ownership in DTIL after the transaction?

Following the purchase, Buehler directly owns 28,137 shares of DTIL.

Did the filing disclose any sales or derivative transactions by the director?

No. The Form 4 lists only an open-market purchase of common stock and shows no derivative activity.

Was the purchase made under a Rule 10b5-1 trading plan?

The filing does not indicate the use of a Rule 10b5-1(c) plan; the relevant checkbox was left blank.
Stock DTIL logo
Precision Biosciences

NASDAQ:DTIL

DTIL Rankings

#7948 Ranked by Market Cap
N/A Ranked by Dividends

DTIL Latest News

Jul 16, 2025
Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic
Jun 25, 2025
Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy
May 15, 2025
Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
May 14, 2025
Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 8, 2025
Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025

DTIL Latest SEC Filings

Jul 8, 2025
[Form 4] Precision BioSciences, Inc. Insider Trading Activity
Jul 3, 2025
[144] Precision BioSciences, Inc. SEC Filing
Jun 27, 2025
[Form 4] Precision BioSciences, Inc. Insider Trading Activity

DTIL Stock Data

53.56M
9.71M
12.23%
50.49%
9.6%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
DURHAM